Eterna Therapeutics (ERNA) Competitors $1.04 -0.05 (-4.59%) (As of 11/1/2024 ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends ERNA vs. CYTH, CGTX, MRNS, MEIP, PMN, BFRG, HCWB, ATHA, COCP, and FNCHShould you be buying Eterna Therapeutics stock or one of its competitors? The main competitors of Eterna Therapeutics include Cyclo Therapeutics (CYTH), Cognition Therapeutics (CGTX), Marinus Pharmaceuticals (MRNS), MEI Pharma (MEIP), ProMIS Neurosciences (PMN), Bullfrog AI (BFRG), HCW Biologics (HCWB), Athira Pharma (ATHA), Cocrystal Pharma (COCP), and Finch Therapeutics Group (FNCH). These companies are all part of the "pharmaceutical products" industry. Eterna Therapeutics vs. Cyclo Therapeutics Cognition Therapeutics Marinus Pharmaceuticals MEI Pharma ProMIS Neurosciences Bullfrog AI HCW Biologics Athira Pharma Cocrystal Pharma Finch Therapeutics Group Eterna Therapeutics (NASDAQ:ERNA) and Cyclo Therapeutics (NASDAQ:CYTH) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, community ranking, earnings, risk, media sentiment, analyst recommendations and institutional ownership. Which has better valuation & earnings, ERNA or CYTH? Cyclo Therapeutics has higher revenue and earnings than Eterna Therapeutics. Cyclo Therapeutics is trading at a lower price-to-earnings ratio than Eterna Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEterna Therapeutics$70K80.38-$21.67M-$4.42-0.24Cyclo Therapeutics$1.08M19.18-$20.06M-$0.88-0.82 Does the media prefer ERNA or CYTH? In the previous week, Eterna Therapeutics had 2 more articles in the media than Cyclo Therapeutics. MarketBeat recorded 2 mentions for Eterna Therapeutics and 0 mentions for Cyclo Therapeutics. Cyclo Therapeutics' average media sentiment score of 0.00 beat Eterna Therapeutics' score of -0.33 indicating that Cyclo Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Eterna Therapeutics Neutral Cyclo Therapeutics Neutral Do analysts rate ERNA or CYTH? Cyclo Therapeutics has a consensus target price of $0.95, indicating a potential upside of 31.65%. Given Cyclo Therapeutics' higher possible upside, analysts clearly believe Cyclo Therapeutics is more favorable than Eterna Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Eterna Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) N/ACyclo Therapeutics 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.33 Does the MarketBeat Community prefer ERNA or CYTH? Cyclo Therapeutics received 10 more outperform votes than Eterna Therapeutics when rated by MarketBeat users. CompanyUnderperformOutperformEterna TherapeuticsN/AN/ACyclo TherapeuticsOutperform Votes1071.43% Underperform Votes428.57% Is ERNA or CYTH more profitable? Cyclo Therapeutics has a net margin of -1,830.27% compared to Eterna Therapeutics' net margin of -14,765.43%. Eterna Therapeutics' return on equity of -1,466.71% beat Cyclo Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Eterna Therapeutics-14,765.43% -1,466.71% -48.44% Cyclo Therapeutics -1,830.27%-2,741.89%-269.95% Do institutionals and insiders believe in ERNA or CYTH? 70.6% of Eterna Therapeutics shares are owned by institutional investors. Comparatively, 68.6% of Cyclo Therapeutics shares are owned by institutional investors. 4.5% of Eterna Therapeutics shares are owned by company insiders. Comparatively, 29.8% of Cyclo Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Which has more risk and volatility, ERNA or CYTH? Eterna Therapeutics has a beta of 4.39, suggesting that its stock price is 339% more volatile than the S&P 500. Comparatively, Cyclo Therapeutics has a beta of -0.38, suggesting that its stock price is 138% less volatile than the S&P 500. SummaryCyclo Therapeutics beats Eterna Therapeutics on 9 of the 16 factors compared between the two stocks. Ad Porter & CompanyBanking failure dead aheadIf you missed it, my emergency election broadcast is now available - but will be removed soonClick here to watch it now. Get Eterna Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ERNA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ERNA vs. The Competition Export to ExcelMetricEterna TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.63M$7.42B$5.50B$8.53BDividend YieldN/A7.96%5.13%4.14%P/E Ratio-0.249.84114.8315.12Price / Sales80.38401.431,497.30100.87Price / CashN/A47.3939.6834.09Price / Book2.545.324.665.02Net Income-$21.67M$153.56M$119.06M$225.46M7 Day Performance2.87%0.13%0.80%0.37%1 Month Performance7.22%15.23%5.65%3.57%1 Year Performance-21.80%41.14%36.75%29.43% Eterna Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ERNAEterna Therapeutics0.2427 of 5 stars$1.04-4.6%N/A-15.4%$5.63M$70,000.00-0.2410Short Interest ↑News CoverageCYTHCyclo Therapeutics2.7002 of 5 stars$0.76+1.7%$0.95+25.4%-25.2%$21.68M$1.13M-0.869Positive NewsGap UpCGTXCognition Therapeutics3.6973 of 5 stars$0.52-8.7%$8.00+1,450.7%-56.8%$20.67MN/A-0.5520Upcoming EarningsAnalyst ForecastShort Interest ↓News CoverageGap UpMRNSMarinus Pharmaceuticals4.1193 of 5 stars$0.38-7.4%$6.07+1,519.0%-95.1%$20.60M$30.26M-0.14110Upcoming EarningsAnalyst ForecastHigh Trading VolumeMEIPMEI Pharma4.567 of 5 stars$3.00+9.9%$7.00+133.3%-56.3%$19.99M$65.30M1.12100Analyst ForecastNews CoverageGap DownHigh Trading VolumePMNProMIS Neurosciences0.6803 of 5 stars$1.03+0.3%N/A-33.1%$19.44M$10,000.00-1.716News CoverageBFRGBullfrog AI1.19 of 5 stars$2.42+3.0%N/A-14.9%$19.00M$65,000.00-2.884Gap UpHCWBHCW Biologics1.1279 of 5 stars$0.50+8.1%N/A-73.0%$18.91M$3.92M-0.4840Short Interest ↓Gap UpATHAAthira Pharma2.5581 of 5 stars$0.49+5.4%$13.83+2,705.9%-65.4%$18.90MN/A-0.1740Gap UpCOCPCocrystal Pharma2.7036 of 5 stars$1.83+1.1%$7.00+282.5%+4.2%$18.62MN/A-1.0310Positive NewsFNCHFinch Therapeutics GroupN/A$11.55-3.3%N/A+231.1%$18.60M$110,000.00-1.31190Gap Down Related Companies and Tools Related Companies CYTH Alternatives CGTX Alternatives MRNS Alternatives MEIP Alternatives PMN Alternatives BFRG Alternatives HCWB Alternatives ATHA Alternatives COCP Alternatives FNCH Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ERNA) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredThe centerpiece of Trump’s crypto’s masterplan …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin...Weiss Ratings | SponsoredHow Will You Survive A Post Election Retirement Heist?The clock is ticking, and your life savings are in an extremely vulnerable position. We are a few days away...American Hartford Gold Group | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredI was wrong. Dead wrong. I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eterna Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eterna Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ERNA Stock Alerts